Tempus AI's stock plummeted 5.60% during intraday trading on Thursday.
The decline appears to be a partial retracement after the stock surged over 10% in the prior session following the announcement of a co-branded whole-genome sequencing product with Predicta Biosciences. Investors are likely taking profits after the recent gains.
The Life Sciences Tools & Services sector showed mixed performance, but Tempus AI's movement is primarily attributed to profit-taking activity.